At Davipharm’s early June Townhall, more than 450 employees joined onsite at the factory and online, coming together to review key business highlights and achievements.

IQVIA Q1/2026 data shows Davipharm in the Top 5 domestic market across key product groups (excluding injectables), with Jan-May 2026 sales growth by 27% year-on-year.

Strong commercial execution continued with nationwide activities across pharmacies and hospitals attracting thousands of HCPs.

Manufacturing reached a historic peak performance with 65 million tablets more than the same period last year, and over 650 days without accident – a strong reflection of operational excellence and safety.

Expansion projects for exports to Europe and the Eurasian Economic Union continue to progress, strengthening Davipharm’s global footprint.

Investment in R&D equipment and lab renovation has built a more modern and safer working environment for our employees.

With a strong commitment to people development, Davipharm continues to strengthen its position as as a best place to work through team building initiatives, training, First Manager & Future Leader programs, Adamed Values Contest, and a happier workplace culture.